Skip to main content
. Author manuscript; available in PMC: 2023 Aug 15.
Published in final edited form as: Cancer Res. 2023 Feb 15;83(4):626–640. doi: 10.1158/0008-5472.CAN-22-0232

Figure 6. Mass cytometry reveals unique early immune response to dual targeting of PDL1 and CTLA4.

Figure 6.

A. Experimental scheme of MYC-HCC treatment with IgG control (n=3), PDL1 antibody (n=3), CTLA4 antibody (n=2), or their combination (n=4) for 1 week, followed by mass cytometry analysis (created using Biorender.com).

B. tSNE plot grouped by major immune subsets identified in the tumor immune microenvironment.

C. tSNE plot showing the visual representation of myeloid marker expression between MYC-HCC treated with IgG control (n=3), PDL1 antibody (n=3), CTLA4 antibody (n=2), or their combination (n=4)

D. Boxplots shows quantification of CCR2+/Ly6High M1-Like Macrophages, Ly6C expression in the macrophages, abundance of PDL1+/Ly6CLow/CCR2Low M2-Like Macrophages and myeloid derived suppressor cells (MDSCs) in MYC-HCC treated with IgG control (n=3), PDL1 antibody (n=3), CTLA4 antibody (n=2), or their combination (n=4) respectively.

E. Boxplots show quantification of CD40 expression in different myeloid subsets in MYC-HCC treated with IgG control (n=3), PDL1 antibody (n=3), CTLA4 antibody (n=2), or their combination (n=4) respectively.

F. Boxplots shows quantification of MHCII expression in CD39+ and PDL1+ M2-Like Macrophages in MYC-HCC treated with IgG control (n=3), PDL1 antibody (n=3), CTLA4 antibody (n=2), or their combination (n=4) respectively.